The next generation of cancer care: Working to defeat — and even prevent — the disease
When Peter Lebowitz, M.D., Ph.D., was an assistant professor of medicine at Georgetown University Medical Center in 2004, he began to wonder why chemotherapy—the prevailing method of treating cancer since the 1960s — continued to be the most commonly used therapy.
“[With chemotherapy], some tumors melt away, but with others, it’s a different story,” says Lebowitz, who’s now Global Head of Oncology at Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. From his perspective, there had to be other approaches to eradicating a scourge as multifaceted as cancer.
“I promised myself I would dedicate my career to helping bring about those kinds of novel approaches,” he says. Today, nearly 400 scientists at Janssen are helping Lebowitz with that mission.